Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2016 2
2017 1
2018 1
2019 1
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean paul a k. P. Reis (21 results)?
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, Damasceno A, Avezum A, Dans AML, Gitura B, Hu D, Kamanzi ER, Maklady F, Fana G, Gonzalez-Hermosillo JA, Musuku J, Kazmi K, Zühlke L, Gondwe L, Ma C, Paniagua M, Ogah OS, Molefe-Baikai OJ, Lwabi P, Chillo P, Sharma SK, Cabral TTJ, Tarhuni WM, Benz A, van Eikels M, Krol A, Pattath D, Balasubramanian K, Rangarajan S, Ramasundarahettige C, Mayosi B, Yusuf S; INVICTUS Investigators. Connolly SJ, et al. N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28. N Engl J Med. 2022. PMID: 36036525 Clinical Trial.
Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-out …
Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. …
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
Tomás CC, Oliveira E, Sousa D, Uba-Chupel M, Furtado G, Rocha C, Teixeira A, Ferreira P, Alves C, Gisin S, Catarino E, Carvalho N, Coucelo T, Bonfim L, Silva C, Franco D, González JA, Jardim HG, Silva R, Baixinho CL, Presado MªH, Marques MªF, Cardoso ME, Cunha M, Mendes J, Xavier A, Galhardo A, Couto M, Frade JG, Nunes C, Mesquita JR, Nascimento MS, Gonçalves G, Castro C, Mártires A, Monteiro MªJ, Rainho C, Caballero FP, Monago FM, Guerrero JT, Monago RM, Trigo AP, Gutierrez ML, Milanés GM, Reina MG, Villanueva AG, Piñero AS, Aliseda IR, Ramirez FB, Ribeiro A, Quelhas A, Manso C, Caballero FP, Guerrero JT, Monago FM, Santos RB, Jimenez NR, Nuñez CG, Gomez IR, Fernandez MªJL, Marquez LA, Moreno AL, Huertas MªJT, Ramirez FB, Seabra D, Salvador MªC, Braga L, Parreira P, Salgueiro-Oliveira A, Arreguy-Sena C, Oliveira BF, Henriques MªA, Santos J, Lebre S, Marques A, Festas C, Rodrigues S, Ribeiro A, Lumini J, Figueiredo AG, Hernandez-Martinez FJ, Campi L, Quintana-Montesdeoca MªP, Jimenez-Diaz JF, Rodriguez-De-Vera BC, Parente A, Mata MªA, Pereira AMª, Fernandes A, Brás M, Pinto MªR, Parreira P, Basto ML, Rei AC, Mónico LM, Sousa G, Morna C, Freitas O, Freitas G, Jardim A, Vasconcelos … See abstract for full author list ➔ Tomás CC, et al. BMC Health Serv Res. 2016 Jul 6;16 Suppl 3(Suppl 3):200. doi: 10.1186/s12913-016-1423-5. BMC Health Serv Res. 2016. PMID: 27409075 Free PMC article.
Maia, Michelle T. Oliveira, Anderson R. Sousa, Paulo P. Ferreira, Luci S. Lopes, Eujcely C. Santiago O45 Community Health screenings and self-reported chronic diseases Silvia Monteiro, Angelo Jesus, Armanda Colaco, Antonio Carvalho, Rita P. ...Padilha, Jorge Valente …
Maia, Michelle T. Oliveira, Anderson R. Sousa, Paulo P. Ferreira, Luci S. Lopes, Eujcely C. Santiago O45 Community Health screenings …
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
In the planned primary analysis, which was performed after 437 primary end-point events had occurred, the median metastasis-free survival was 40.4 months with darolutamide, as compared with 18.4 months with placebo (hazard ratio for metastasis or death in the darolutamide group, …
In the planned primary analysis, which was performed after 437 primary end-point events had occurred, the median metastasis-free survival wa …
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
The risk of death was significantly lower, by 31%, in the darolutamide group than in the placebo group (hazard ratio for death, 0.69; 95% CI, 0.53 to 0.88; P = 0.003). Darolutamide was also associated with a significant benefit with respect to all other secondary end point …
The risk of death was significantly lower, by 31%, in the darolutamide group than in the placebo group (hazard ratio for death, 0.69; 95% CI …
Use of cardiac imaging in chronic coronary syndromes: the EURECA Imaging registry.
Neglia D, Liga R, Gimelli A, Podlesnikar T, Cvijić M, Pontone G, Miglioranza MH, Guaricci AI, Seitun S, Clemente A, Sumin A, Vitola J, Saraste A, Paunonen C, Sia CH, Paleev F, Sade LE, Zamorano JL, Maroz-Vadalazhskaya N, Anagnostopoulos C, Macedo F, Knuuti J, Edvardsen T, Cosyns B, Petersen SE, Magne J, Laroche C, Berlè C, Popescu BA, Delgado V; EURECA Investigators. Neglia D, et al. Eur Heart J. 2023 Jan 7;44(2):142-158. doi: 10.1093/eurheartj/ehac640. Eur Heart J. 2023. PMID: 36452988

In 44% of patients, the overall diagnostic process did not adopt the GL. In these patients, referral to stress imaging (21% vs. 58%; P < 0.001) or CTCA (17% vs. 30%; P < 0.001) was less frequent, while exercise ECG (43% vs. 22%; P < 0.001) and ICA (4

…
In 44% of patients, the overall diagnostic process did not adopt the GL. In these patients, referral to stress imaging (21% vs. 58%; P …
Potential Health Risks of Macro- and Microelements in Commercial Medicinal Plants Used to Treatment of Diabetes.
de Souza ID, Melo ESP, Nascimento VA, Pereira HS, Silva KRN, Espindola PR, Tschinkel PFS, Ramos EM, Reis FJM, Ramos IB, Paula FG, Oliveira KRW, Lima CD, Nunes ÂA, do Nascimento VA. de Souza ID, et al. Biomed Res Int. 2021 Mar 31;2021:6678931. doi: 10.1155/2021/6678931. eCollection 2021. Biomed Res Int. 2021. PMID: 33869633 Free PMC article.
The hazard quotient (HQ) method was used to access the human health risks posed by heavy metal through tea consumption. The results revealed the presence of K, Mg, Na, P, Al, Fe, Zn, Mn, Cu, Ni, and Se in dry samples and plant teas. The dry plants have high concentr …
The hazard quotient (HQ) method was used to access the human health risks posed by heavy metal through tea consumption. The results revealed …
Observation of a New Excited D_{s}^{+} Meson in B^{0}D^{-}D^{+}K^{+}pi^{-} Decays.
Aaij R, Abellán Beteta C, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alkhazov G, Alvarez Cartelle P, Amato S, Amhis Y, An L, Anderlini L, Andreianov A, Andreotti M, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Baker S, Baladron Rodriguez P, Balagura V, Baldini W, Baptista Leite J, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Becker M, Bedeschi F, Bediaga I, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein HC, Bertella C, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler MO, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Bifani S, Billoir P, Birch M, Bishop FCR, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodski M,… See abstract for full author list ➔ Aaij R, et al. Phys Rev Lett. 2021 Mar 26;126(12):122002. doi: 10.1103/PhysRevLett.126.122002. Phys Rev Lett. 2021. PMID: 33834812 Free article.
Using pp collision data corresponding to an integrated luminosity of 5.4 fb^{-1} collected with the LHCb detector at a center-of-mass energy of 13 TeV, the B^{0}D^{-}D^{+}K^{+}pi^{-} decay is studied. A new excited D_{s}^{+} meson is observed decaying into the D^{+}K …
Using pp collision data corresponding to an integrated luminosity of 5.4 fb^{-1} collected with the LHCb detector at a center-of-mass energy …
Studies of the resonance structure in D 0 → K ∓ π ± π ± π ∓ decays.
Aaij R, Adeva B, Adinolfi M, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Ali S, Alkhazov G, Alvarez Cartelle P, Alves AA Jr, Amato S, Amerio S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews JE, Appleby RB, Archilli F, d'Argent P, Arnau Romeu J, Artamonov A, Artuso M, Aslanides E, Atzeni M, Auriemma G, Baalouch M, Babuschkin I, Bachmann S, Back JJ, Badalov A, Baesso C, Baker S, Balagura V, Baldini W, Baranov A, Barlow RJ, Barschel C, Barsuk S, Barter W, Baryshnikov F, Batozskaya V, Battista V, Bay A, Beaucourt L, Beddow J, Bedeschi F, Bediaga I, Beiter A, Bel LJ, Beliy N, Bellee V, Belloli N, Belous K, Belyaev I, Ben-Haim E, Bencivenni G, Benson S, Beranek S, Berezhnoy A, Bernet R, Berninghoff D, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler MO, van Beuzekom M, Bezshyiko I, Bifani S, Billoir P, Birnkraut A, Bizzeti A, Bjørn M, Blake T, Blanc F, Blusk S, Bocci V, Boettcher T, Bondar A, Bondar N, Bordyuzhin I, Borghi S, Borisyak M, Borsato M, Bossu F, Boubdir M, Bowcock TJV, Bowen E, Bozzi C, Braun S, Brodzicka J, Brundu D, Buchanan E, Burr C, Bursche A, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calladine R, Calvi… See abstract for full author list ➔ Aaij R, et al. Eur Phys J C Part Fields. 2018;78(6):443. doi: 10.1140/epjc/s10052-018-5758-4. Epub 2018 Jun 2. Eur Phys J C Part Fields. 2018. PMID: 30956546 Free PMC article.
The largest contributions to both decay amplitudes are found to come from axial resonances, with decay modes D0 a1(1260)+K- and D0 K1(1270/1400)+pi- being prominent in D0 K-pi+pi+pi- and D0 K+pi-pi-pi+ , respectively. Precise measurements of the lineshape par …
The largest contributions to both decay amplitudes are found to come from axial resonances, with decay modes D0 a1(1260)+K- and D0 K1 …
Determination of the sign of the decay width difference in the B(s)(0) system.
Aaij R, Abellan Beteta C, Adeva B, Adinolfi M, Adrover C, Affolder A, Ajaltouni Z, Albrecht J, Alessio F, Alexander M, Alkhazov G, Alvarez Cartelle P, Alves AA Jr, Amato S, Amhis Y, Anderson J, Appleby RB, Aquines Gutierrez O, Archilli F, Arrabito L, Artamonov A, Artuso M, Aslanides E, Auriemma G, Bachmann S, Back JJ, Bailey DS, Balagura V, Baldini W, Barlow RJ, Barschel C, Barsuk S, Barter W, Bates A, Bauer C, Bauer T, Bay A, Bediaga I, Belogurov S, Belous K, Belyaev I, Ben-Haim E, Benayoun M, Bencivenni G, Benson S, Benton J, Bernet R, Bettler MO, van Beuzekom M, Bien A, Bifani S, Bird T, Bizzeti A, Bjørnstad PM, Blake T, Blanc F, Blanks C, Blouw J, Blusk S, Bobrov A, Bocci V, Bondar A, Bondar N, Bonivento W, Borghi S, Borgia A, Bowcock TJ, Bozzi C, Brambach T, van den Brand J, Bressieux J, Brett D, Britsch M, Britton T, Brook NH, Brown H, de Bruyn K, Büchler-Germann A, Burducea I, Bursche A, Buytaert J, Cadeddu S, Callot O, Calvi M, Calvo Gomez M, Camboni A, Campana P, Carbone A, Carboni G, Cardinale R, Cardini A, Carson L, Carvalho Akiba K, Casse G, Cattaneo M, Cauet Ch, Charles M, Charpentier P, Chiapolini N, Ciba K, Cid Vidal X, Ciezarek G, Clarke PE, Clemencic M, Cliff HV, … See abstract for full author list ➔ Aaij R, et al. Phys Rev Lett. 2012 Jun 15;108(24):241801. doi: 10.1103/PhysRevLett.108.241801. Epub 2012 Jun 11. Phys Rev Lett. 2012. PMID: 23004259 Free article.
The interference between the K+ K- S-wave and P-wave amplitudes in B(s)(0) J/psiK+ K- decays with the K+ K- pairs in the region around the (1020) resonance is used to determine the variation of the difference of the strong phase between t …
The interference between the K+ K- S-wave and P-wave amplitudes in B(s)(0) J/psiK+ K- decays with the K+ …
14 results